MedTrace Logo

SGLT2 Inhibition: Uric Acid Excretion Study

NCT05210517 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-05-01

No results posted yet for this study

Summary

The current study investigates the effects of SGLT2 inhibitor empagliflozin on uric acid excretion.

Conditions

Interventions

DRUG

Empagliflozin 25 MG

25 once daily one week treatment

DRUG

Benzbromaron

100 mg once daily 1 one week treatment

DRUG

Empagliflozin 25 MG + benzbromarone 100 mg

combined treatment once daily for one week

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-06-08
Completion
2021-09-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05210517 on ClinicalTrials.gov